NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical…
MAINZ, GERMANY, December 21, 2022 — BioNTech SE (Nasdaq: BNTX, “BioNTech”) reached the next milestone in the establishment of scalable…
Brain Activate - ENERGY Gel Brain Activate - ENERGY Gel is a rapidly absorbed focus and cognitive enhancer that is…
Further analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows…
AUSTIN, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) announced today that a valued and long-time…
ST. LOUIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in robotic technologies for the treatment…
– Cohort 4 Dosing Stopped per Clinical Trial Protocol due to Dose-Limiting Toxicities – – Plan to Dose Additional Participants…
FDA granted IND clearance for IVS-3001, Invectys’s lead engineered anti-HLA-G CAR-T cell therapy, for the treatment of patients with solid…
Phase 3, registrational studies remain on track for first half of 2023 topline data readoutSCOTTSDALE, Ariz., Dec. 20, 2022 (GLOBE…
LONDON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T…